SLDB Q2 2022 Earnings — Solid Biosciences Inc. Revenue & Financial Results | Market Cap Arena

SLDBSolid Biosciences Inc.

$644M

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$6M+71.6% YoY

Gross Profit

$6M100.0% margin

Operating Income

-$25M-411.4% margin

Net Income

-$25M-406.7% margin

EPS (Diluted)

$-3.30

QoQ Revenue Growth

+220.5%

Cash Flow

Operating Cash Flow

-$16M

Free Cash Flow

-$17M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$208M

Total Liabilities

$46M

Stockholders' Equity

$162M

Cash & Equivalents

$54M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$6M	$4M	+71.6%
Gross Profit	$6M	$4M	+71.6%
Operating Income	-$25M	-$19M	-35.8%
Net Income	-$25M	-$19M	-34.2%